ABSTRACT
Background: In French Polynesia, hepatitis B virus (HBV) infection appears as a major risk factor for hepatocellular carcinoma (HCC), which detection rate in the Austral archipelago is among the highest in the world. Through a nationally representative cross-sectional survey of the adult population, this study aimed at assessing the prevalence of HBV, but also hepatitis C virus (HCV), and hepatitis delta virus (HDV). Methods: A total of 1942 blood samples from participants aged 18-69 years were tested for anti-HBc, anti-HBs, HBsAg, anti-HCV IgG, and HDV RNA. Complete genome sequencing of detected HBV strains was performed. Findings: Among participants, 315/1834, 582/1834, 33/1834, 0/1857, and 0/33 tested positive for anti-HBc, anti-HBs, HBsAg, anti-HCV IgG, and HDV RNA, respectively. The population prevalence of HBsAg was estimated at 1.0% (95% CI: 0.6-1.7). All HBsAg carriers were born in French Polynesia before vaccination at birth became mandatory. In multivariate analyses, identified factors associated with HBsAg carriage included: the archipelago of residence (p < 0.0001), age (p < 0.0001), and education level (p = 0.0077). HBV genotypes B, C, and F were detected. Interpretation: French Polynesia has a low endemicity level of HBV and its population may be considered at low risk for HCV and HDV infection. However, prevalence of HBsAg was found concerning in Austral (3.8%; 95% CI: 1.9-7.5) and Marquesas (6.5%; 95% CI: 3.8-11) archipelagoes. In the Austral archipelago, the presence of genotype C may account for the elevated rate of HCC. Our findings warrant more efforts to improve access to detection, prevention and care to people born before the systematic vaccination policy application, and residing in higher-risk areas, to achieve HBV elimination in French Polynesia. Funding: Research Delegation of French Polynesia.
ABSTRACT
BACKGROUND: French Polynesia (FP) comprises 75 inhabited islands scattered across five archipelagos. Between July and October 2021, the SARS-CoV-2 Delta variant triggered a much stronger second epidemic wave in FP than the original Wuhan strain, which was dominant from August 2020 to March 2021. Although previous seroprevalence surveys made it possible to determine the proportion of the population infected by SARS-CoV-2 on the two most populated islands (Tahiti and Moorea) after the first (20.6% in Tahiti and 9.4% in Moorea) and second (57.7% in Tahiti) epidemic waves, no data are available for more remote islands. We used blood samples and personal data collected before, during, and after the second wave from inhabitants of several islands within the five archipelagos to assess the prevalence of SARS-CoV-2 infections and identify associated factors. METHODS: Blood samples and personal data were collected between April and December 2021 as part of the MATAEA study, a cross-sectional survey conducted on a random sample of the adult population representative of the five FP archipelagos and stratified by age and gender. IgG antibodies targeting the SARS-CoV-2 nucleocapsid (N) protein were detected using a recombinant antigen-based microsphere immunoassay. Factors associated with anti-SARS-CoV-2-N seropositivity were identified using logistic regression models. RESULTS: Of 1,120 participants, 503 (44.9%) tested positive for anti-SARS-CoV-2-N antibodies, corresponding to a weighted prevalence of 56.8% for the FP population aged 18-69 years. The seroprevalence increased from 21.9% to 62.1% before and during/after the Delta wave. Of these infections, only 28.4% had been diagnosed by health professionals. The odds of being seropositive were lower in males, participants recruited before the Delta wave, those who had never been married, those with a diagnosed respiratory allergy, smokers, and those vaccinated against COVID-19. CONCLUSIONS: Our results confirm the high impact of the Delta wave in FP. By the end of 2021, 56.8% of the FP population aged 18-69 years had been infected by SARS-CoV-2; the majority of these infections went undetected. Individuals with respiratory allergies were found to be less susceptible to SARS-CoV-2 infection.
Subject(s)
COVID-19 , SARS-CoV-2 , Adult , Male , Humans , Cross-Sectional Studies , COVID-19/epidemiology , Seroepidemiologic Studies , Polynesia/epidemiology , Antibodies, ViralABSTRACT
BACKGROUND: Effective Coronavirus Disease 2019 (COVID-19) response relies on good knowledge of population infection dynamics, but owing to under-ascertainment and delays in symptom-based reporting, obtaining reliable infection data has typically required large dedicated local population studies. Although many countries implemented Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) testing among travellers, it remains unclear how accurately arrival testing data can capture international patterns of infection, because those arrival testing data were rarely reported systematically, and predeparture testing was often in place as well, leading to nonrepresentative infection status among arrivals. METHODS AND FINDINGS: In French Polynesia, testing data were reported systematically with enforced predeparture testing type and timing, making it possible to adjust for nonrepresentative infection status among arrivals. Combining statistical models of polymerase chain reaction (PCR) positivity with data on international travel protocols, we reconstructed estimates of prevalence at departure using only testing data from arrivals. We then applied this estimation approach to the United States of America and France, using data from over 220,000 tests from travellers arriving into French Polynesia between July 2020 and March 2022. We estimated a peak infection prevalence at departure of 2.1% (95% credible interval: 1.7, 2.6%) in France and 1% (95% CrI: 0.63, 1.4%) in the USA in late 2020/early 2021, with prevalence of 4.6% (95% CrI: 3.9, 5.2%) and 4.3% (95% CrI: 3.6, 5%), respectively, estimated for the Omicron BA.1 waves in early 2022. We found that our infection estimates were a leading indicator of later reported case dynamics, as well as being consistent with subsequent observed changes in seroprevalence over time. We did not have linked data on traveller demography or unbiased domestic infection estimates (e.g., from random community infection surveys) in the USA and France. However, our methodology would allow for the incorporation of prior data from additional sources if available in future. CONCLUSIONS: As well as elucidating previously unmeasured infection dynamics in these countries, our analysis provides a proof-of-concept for scalable and accurate leading indicator of global infections during future pandemics.
Subject(s)
COVID-19 , SARS-CoV-2 , Humans , COVID-19/diagnosis , COVID-19/epidemiology , Prevalence , Seroepidemiologic Studies , France/epidemiologyABSTRACT
In French Polynesia, the first case of SARS-CoV-2 infection was detected on March 10th, 2020, in a resident returning from France. Between March 28th and July 14th, international air traffic was interrupted and local transmission of SARS-CoV-2 was brought under control, with only 62 cases recorded. The main challenge for reopening the air border without requiring travelers to quarantine on arrival was to limit the risk of re-introducing SARS-CoV-2. Specific measures were implemented, including the obligation for all travelers to have a negative RT-PCR test for SARS-CoV-2 carried out within 3 days before departure, and to perform another RT-PCR testing 4 days after arrival. Because of limitation in available medical staff, travelers were provided a kit allowing self-collection of oral and nasal swabs. In addition to increase our testing capacity, self-collected samples from up to 10 travelers were pooled before RNA extraction and RT-PCR testing. When a pool tested positive, RNA extraction and RT-PCR were performed on each individual sample. We report here the results of COVID-19 surveillance (COV-CHECK PORINETIA) conducted between July 15th, 2020, and February 15th, 2021, in travelers using self-collection and pooling approaches. We tested 5,982 pools comprising 59,490 individual samples, and detected 273 (0.46%) travelers positive for SARS-CoV-2. A mean difference of 1.17 Ct (CI 95% 0.93-1.41) was found between positive individual samples and pools (N = 50), probably related to the volume of samples used for RNA extraction (200 µL versus 50 µL, respectively). Retrospective testing of positive samples self-collected from October 20th, 2020, using variants-specific amplification kit and spike gene sequencing, found at least 6 residents infected by the Alpha variant. Self-collection and pooling approaches allowed large-scale screening for SARS-CoV-2 using less human, material and financial resources. Moreover, this strategy allowed detecting the introduction of SARS-CoV-2 variants of concern in French Polynesia.
Subject(s)
COVID-19 Testing/methods , COVID-19/diagnosis , Mass Screening/methods , Population Surveillance/methods , Specimen Handling/methods , Travel , COVID-19/epidemiology , COVID-19/virology , COVID-19 Testing/instrumentation , Epidemics/prevention & control , France/epidemiology , Humans , Polynesia/epidemiology , Prospective Studies , RNA, Viral/genetics , RNA, Viral/isolation & purification , Reverse Transcriptase Polymerase Chain Reaction/methods , SARS-CoV-2/genetics , SARS-CoV-2/physiology , Specimen Handling/instrumentationABSTRACT
Zika virus (ZIKV) has caused large, brief outbreaks in isolated populations, however ZIKV can also persist at low levels over multiple years. The reasons for these diverse transmission dynamics remain poorly understood. In Fiji, which has experienced multiple large single-season dengue epidemics, there was evidence of multi-year transmission of ZIKV between 2013 and 2017. To identify factors that could explain these differences in dynamics between closely related mosquito-borne flaviviruses, we jointly fit a transmission dynamic model to surveillance, serological and molecular data. We estimate that the observed dynamics of ZIKV were the result of two key factors: strong seasonal effects, which created an ecologically optimal time of year for outbreaks; and introduction of ZIKV after this optimal time, which allowed ZIKV transmission to persist over multiple seasons. The ability to jointly fit to multiple data sources could help identify a similar range of possible outbreak dynamics in other settings.
Subject(s)
Flavivirus Infections/epidemiology , Flavivirus Infections/transmission , Animals , Culicidae , Dengue/transmission , Dengue Virus , Disease Outbreaks , Epidemics , Fiji/epidemiology , Flavivirus , Humans , Mosquito Vectors/virology , Seasons , Zika Virus , Zika Virus Infection/epidemiology , Zika Virus Infection/transmissionABSTRACT
It has been commonly assumed that Zika virus (ZIKV) infection confers long-term protection against reinfection, preventing ZIKV from re-emerging in previously affected areas for several years. However, the long-term immune response to ZIKV following an outbreak remains poorly documented. We compared results from eight serological surveys before and after known ZIKV outbreaks in French Polynesia and Fiji, including cross-sectional and longitudinal studies. We found evidence of a decline in seroprevalence in both countries over a two-year period following first reported ZIKV transmission. This decline was concentrated in adults, while high seroprevalence persisted in children. In the Fiji cohort, there was also a significant decline in neutralizing antibody titres against ZIKV, but not against dengue viruses that circulated during the same period.
Subject(s)
Antibodies, Neutralizing , Zika Virus Infection/epidemiology , Zika Virus Infection/immunology , Zika Virus/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Viral/blood , Blood Donors , Child , Child, Preschool , Cross-Sectional Studies , Disease Outbreaks , Fiji/epidemiology , Health Surveys , Humans , Immunoglobulin G/blood , Infant , Infant, Newborn , Longitudinal Studies , Middle Aged , Polynesia/epidemiology , Seroepidemiologic Studies , Young Adult , Zika Virus Infection/transmission , Zika Virus Infection/virologyABSTRACT
OBJECTIVES: In Fiji, autochthonous chikungunya virus (CHIKV) infection was first detected in March 2015. In a previous serosurvey conducted during October-November 2015, we reported a prevalence of anti-CHIKV IgG antibodies of 0.9%. In the present study, we investigated the seroprevalence of CHIKV two years after its emergence in Fiji. METHODS: Sera from 320 residents of Fiji recruited in June 2017, from the same cohort of individuals that participated in the serosurvey in 2015, were tested for the presence of IgG antibodies against CHIKV using a recombinant antigen-based microsphere immunoassay. RESULTS: Between 2015 and 2017, CHIKV seroprevalence among residents increased from 0.9% (3/333) to 12.8% (41/320). Of the participants with available serum samples collected in both 2015 and 2017 (n=200), 31 (15.5%) who were seronegative in 2015 had seroconverted to CHIKV in 2017. CONCLUSIONS: Our findings suggest that low-level transmission of CHIKV occurred during the two years following the emergence of the virus in Fiji. No CHIKV infection has been reported in Fiji since 2017, but due to the presumed low herd immunity of the population, the risk of CHIKV re-emergence is high. Consequently, chikungunya should be considered in the differential diagnosis of acute febrile diseases in Fiji.
Subject(s)
Chikungunya Fever/blood , Chikungunya Fever/epidemiology , Chikungunya virus/isolation & purification , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Viral/blood , Chikungunya Fever/virology , Chikungunya virus/classification , Chikungunya virus/genetics , Chikungunya virus/immunology , Child , Child, Preschool , Female , Fiji/epidemiology , Humans , Immunity, Herd , Male , Middle Aged , Seroconversion , Seroepidemiologic Studies , Young AdultABSTRACT
Zika and chikungunya viruses were first detected in Fiji in 2015. Examining surveillance and phylogenetic and serologic data, we found evidence of low-level transmission of Zika and chikungunya viruses during 2013-2017, in contrast to the major outbreaks caused by closely related virus strains in other Pacific Island countries.
Subject(s)
Chikungunya Fever/epidemiology , Chikungunya Fever/transmission , Chikungunya virus , Zika Virus Infection/epidemiology , Zika Virus Infection/transmission , Zika Virus , Chikungunya Fever/virology , Chikungunya virus/classification , Chikungunya virus/genetics , Disease Outbreaks , Female , Fiji/epidemiology , Humans , Islands , Male , Phylogeny , Population Surveillance , Risk Factors , Sequence Analysis, DNA , Seroepidemiologic Studies , Viral Envelope Proteins/genetics , Zika Virus/classification , Zika Virus/genetics , Zika Virus Infection/virologyABSTRACT
In 1996-97, the last dengue virus serotype 2 (DENV-2) outbreak occurred in French Polynesia. In February 2019, DENV-2 infection was detected in a traveller from New Caledonia. In March, autochthonous DENV-2 infection was diagnosed in two residents. A DENV-2 outbreak was declared on 10 April with 106 cases as at 24 June. Most of the population is not immune to DENV-2; a large epidemic could occur with risk of imported cases in mainland France.
Subject(s)
Dengue Virus/genetics , Dengue Virus/isolation & purification , Dengue/diagnosis , Disease Outbreaks , Mosquito Vectors/virology , RNA, Viral/genetics , Adolescent , Adult , Animals , Dengue/epidemiology , Female , Hospitalization , Humans , Male , Middle Aged , Phylogeny , Polynesia/epidemiology , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Serogroup , Young AdultABSTRACT
A unique outbreak of Ross River virus (RRV) infection was reported in Fiji in 1979. In 2013, RRV seroprevalence among residents was 46.5% (362/778). Of the residents who were seronegative in 2013 and retested in 2015, 10.9% (21/192) had seroconverted to RRV, suggesting ongoing endemic circulation of RRV in Fiji.
Subject(s)
Alphavirus Infections/diagnosis , Ross River virus/immunology , Alphavirus Infections/blood , Alphavirus Infections/epidemiology , Antibodies, Viral/blood , Fiji/epidemiology , Humans , Ross River virus/isolation & purification , Seroepidemiologic StudiesABSTRACT
We investigated dengue and chikungunya virus antibody seroprevalence in French Polynesia during 2014-2015. Dengue virus seroprevalence was ≈60% among schoolchildren and >83% among the general population; chikungunya virus seroprevalence was <3% before and 76% after Zika virus emergence (2013). Dengue virus herd immunity may affect Zika virus infection and pathogenesis.
Subject(s)
Antibodies, Viral/immunology , Chikungunya Fever/epidemiology , Chikungunya Fever/immunology , Chikungunya virus/immunology , Dengue Virus/immunology , Dengue/epidemiology , Dengue/immunology , Adolescent , Adult , Antibodies, Neutralizing/immunology , Chikungunya Fever/history , Child , Child, Preschool , Dengue/history , History, 21st Century , Humans , Middle Aged , Neutralization Tests , Polynesia/epidemiology , Seroepidemiologic Studies , Young AdultABSTRACT
Ross River virus (RRV), spread by Aedes and Culex mosquitoes, is the most commonly transmitted arbovirus in Australia. A serosurvey of blood donors in French Polynesia during 2011-2013 suggested that RRV circulated without being detected. We report RRV circulation in French Polynesia based on further screening of blood samples collected during 2014-2015.
Subject(s)
Aedes/virology , Alphavirus Infections/epidemiology , Antibodies, Viral/blood , Culex/virology , Immunoglobulin G/blood , Insect Vectors/virology , Ross River virus/isolation & purification , Adolescent , Adult , Aged , Aged, 80 and over , Alphavirus Infections/transmission , Alphavirus Infections/virology , Animals , Asymptomatic Diseases , Blood Donors , Child , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Polynesia/epidemiology , Ross River virus/immunology , Seroepidemiologic StudiesABSTRACT
In French Polynesia, the four serotypes of dengue virus (DENV-1 to -4) have caused 14 epidemics since the mid-1940s. From the end of 2016, an increasing number of Pacific Island Countries and Territories have reported DENV-2 outbreaks and in February 2017, DENV-2 infection was detected in French Polynesia in three travellers from Vanuatu. As DENV-2 has not been circulating in French Polynesia since December 2000, there is high risk for an outbreak to occur.
Subject(s)
Dengue Virus/genetics , Dengue/epidemiology , Disease Outbreaks , RNA, Viral/genetics , Dengue/virology , Humans , Phylogeny , Polynesia/epidemiology , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Risk , SerogroupABSTRACT
OBJECTIVES: An epidemic of Ross River virus (RRV) occurred in the South Pacific in 1979-1980, but RRV has not been thought to occur endemically outside Australia and Papua New Guinea. A seroprevalence study was conducted to determine whether RRV has circulated in American Samoa since 1980. METHODS: RRV ELISA IgG was performed on 200 serum samples collected in American Samoa in 2010; seroneutralization tests were performed on 60 representative samples. RESULTS: Of 196 available ELISA IgG results, 145 (74%, 95% confidence interval 67-80%) were seropositive. Of the 60 samples subjected to seroneutralization testing, none of the 15 ELISA IgG-negative and 16 of the 45 ELISA IgG-positive samples neutralized RRV. ELISA IgG seroprevalence was higher in persons born before/during the 1979-1980 RRV outbreak (78.3%), but was also high (63.0%) in people born after the outbreak who had lived their entire lives in American Samoa. CONCLUSIONS: This study provides serological evidence that RRV circulation is likely to have occurred in American Samoa after 1980. Considering there are no marsupials in American Samoa, this finding implies that other species are capable of acting as reservoir hosts and indicates the potential for RRV to circulate in a much wider area than those currently recognized.
Subject(s)
Alphavirus Infections/epidemiology , Ross River virus/isolation & purification , Adolescent , Adult , Animals , Antibodies, Viral/blood , Disease Outbreaks , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin G/blood , Male , Pacific Islands/epidemiology , Seroepidemiologic StudiesABSTRACT
During 2013-2014, French Polynesia experienced an outbreak of Zika virus infection. Serosurveys conducted at the end of the outbreak and 18 months later showed lower than expected disease prevalence rates (49%) and asymptomatic:symptomatic case ratios (1:1) in the general population but significantly different prevalence rates (66%) and asymptomatic:symptomatic ratios (1:2) in schoolchildren.
Subject(s)
Disease Outbreaks , Seroepidemiologic Studies , Zika Virus Infection/epidemiology , Zika Virus Infection/virology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Humans , Male , Middle Aged , Polynesia/epidemiology , Young Adult , Zika Virus Infection/bloodABSTRACT
Zika virus (ZIKV) viremia is reported as low and transient; however, these estimates rely on limited data. We report RNA loads in sera collected from symptomatic patients during the 2013-2014 French Polynesian ZIKV outbreak. We performed molecular detection of ZIKV RNA in sera from 747 patients presenting with suspected acute phase ZIKV infection. Among patients with confirmed infection, we analyzed the duration of viremia, assessed viral RNA loads and recorded the main clinical symptoms. A total of 210/747 (28.1%) sera tested positive using a ZIKV-specific RT-PCR. Viral RNA loads in symptomatic patients that ranged from 5 to 3.7 × 106 copies/mL (mean 9.9 × 104 copies/mL) were not related to a particular clinical presentation, and were significantly lower than those previously obtained from asymptomatic ZIKV infected blood donors. The rate of detection of ZIKV RNA in sera from suspected cases of acute phase ZIKV infection was low. ZIKV RNA loads were lower in symptomatic patients compared to asymptomatic blood donors and were lower than RNA loads usually reported in dengue infections. As there is no abrupt onset of symptoms in ZIKV infections, we suggest that infected patients sought for medical attention when viremia was already decreasing or had resolved.
Subject(s)
Disease Outbreaks , RNA, Viral/blood , Viral Load , Zika Virus Infection/epidemiology , Zika Virus Infection/virology , Zika Virus/isolation & purification , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Polynesia/epidemiology , Time Factors , Young Adult , Zika Virus/genetics , Zika Virus Infection/pathologyABSTRACT
BACKGROUND: Saliva and urine have been used for arthropod-borne viruses molecular detection but not yet for chikungunya virus (CHIKV). We investigated the use of saliva and urine for molecular detection of CHIKV during the French Polynesian outbreak. METHODS: During the French Polynesian chikungunya outbreak (2014-2015), we collected the same day blood and saliva samples from 60 patients with probable chikungunya (47 during the 1st week post symptoms onset and 13 after), urine was available for 39 of them. All samples were tested using a CHIKV reverse-transcription PCR. RESULTS: Forty eight patients had confirmed chikungunya. For confirmed chikungunya presenting during the 1st week post symptoms onset, CHIKV RNA was detected from 86.1 % (31/36) of blood, 58.3 % (21/36) of saliva and 8.3 % (2/24) of urine. Detection rate of CHIKV RNA was significantly higher in blood compared to saliva. For confirmed chikungunya presenting after the 1st week post symptoms onset, CHIKV RNA was detected from 8.3 % (1/12) of blood, 8.3 % (1/12) of saliva and 0 % (0/8) of urine. CONCLUSIONS: In contrast to Zika virus (ZIKV), saliva did not increased the detection rate of CHIKV RNA during the 1st week post symptoms onset. In contrast to ZIKV, dengue virus and West Nile virus, urine did not enlarged the window of detection of CHIKV RNA after the 1st week post symptoms onset. Saliva can be used for molecular detection of CHIKV during the 1st week post symptoms onset only if blood is impossible to collect but with a lower sensitivity compared to blood.